SANDUPHQ.BO · BSE
SANDU PHARMACEUTICALS LTD.
₹37
+0.00% (₹0)
Prev. close
₹37
Volume
1,625
As of
25 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About SANDU PHARMACEUTICALS LTD.
Sandu Pharmaceuticals Limited manufactures and sells ayurvedic medicines under the SANDU brand in India and internationally. It offers immunity monsoon kit, sandu balm, sandu aptilift, sandu mahasudarshan kadha, sandu abhayarishta, sandu pathyadi kadha, sandu makarprash, sandu gulkand pravalyukta, sandu acivin herbal antacid, sandu ashwagandharishta, sandu amritarishta, sandu hemocleen excellent blood purifier, and sandu vanari granules. The company also provides mahasudarshan kadha, amritarishta, tab. samshamani vati, pathajeevani, vasa cough syrup, whoopin syrup, somajeevani, drakshasava, stressan, ashwagandharishtam, sandu sitopalasava, makarprash, chyavanprash, and ayush kwath. Its products are used for wellness, respiratory health, digestive health, and muscle and bone health. Sandu Pharmaceuticals Limited was founded in 1899 and is based in Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Balram Vishwanathan C.A.
Headquarters
Mumbai
Employees
258
Website
sandu.inExchange
View on BSE ↗Key stats
Market cap
₹35.75 Cr
P/E ratio (TTM)
18.8
Dividend yield
2.70%
EPS (TTM)
₹1.97
Beta (1Y · daily vs NIFTY 50)
0.61
Beta (5Y · monthly vs NIFTY 50)
1.32
Shares float
29.73 L
EPS · quarter ended Jun 2026
₹0.37
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: Yahoo (no NSE corporate-actions ledger for this listing).
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹58.76 Cr | ₹65.50 Cr | ₹65.35 Cr | ₹67.28 Cr | ₹67.19 Cr | ₹69.93 Cr | |
| EBITDA | ₹2.35 Cr | ₹2.96 Cr | ₹2.81 Cr | ₹2.71 Cr | ₹2.92 Cr | ₹3.44 Cr |
| ₹1.09 Cr | ₹1.59 Cr | ₹1.52 Cr | ₹1.46 Cr | ₹1.55 Cr | ₹1.77 Cr | |
| Diluted EPS | ₹1.54 | ₹1.87 | ₹1.62 | ₹1.51 | ₹1.6 | ₹1.83 |
Depreciation & amortisation, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹54.17 Cr | ₹52.41 Cr | ₹55.72 Cr | ₹55.87 Cr | |
| — | ₹0 | — | ₹6.33 L | ₹47.75 L | ₹41.93 L | |
| Stockholders' equity | — | — | ₹39.24 Cr | ₹40.59 Cr | ₹42.02 Cr | ₹43.67 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Current (short-term) debt, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹22.11 L | ₹75.99 L | ₹95.04 L | ₹6.12 Cr | |
| Investing cash flow | — | — | ₹53.67 L | ₹-1.31 Cr | ₹-17.96 L | ₹-56.88 L |
| — | — | ₹57.91 L | ₹-72.43 L | ₹-46.20 L | ₹-94.32 L | |
| Capital expenditure | — | — | ₹-1.07 Cr | ₹-1.43 Cr | ₹-93.80 L | ₹-72.00 L |
| End cash position | — | — | ₹2.28 Cr | ₹1.00 Cr | ₹1.30 Cr | ₹5.91 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.44 L Cr | ₹1,852.2 | 37.0 | 5.31 | 13.7% | 0.06 | +11.9% | +13.8% |
| Divi's Laboratories Limited | ₹2.55 L Cr | ₹9,619.5 | 87.0 | 15.21 | 15.3% | 0.00 | +12.3% | +63.1% |
| Torrent Pharmaceuticals Limited | ₹1.90 L Cr | ₹4,928.5 | 79.5 | 22.60 | 25.8% | 1.79 | +21.5% | +36.3% |
| Apollo Hospitals Enterprise Limited | ₹1.28 L Cr | ₹8,889 | 62.5 | 13.48 | 20.5% | 0.90 | +15.7% | +16.6% |
| Lenskart Solutions Limited | ₹1.17 L Cr | ₹680.25 | 177.9 | 13.39 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.17 L Cr | ₹1,180.3 | 26.1 | 4.31 | 18.6% | 0.46 | +18.4% | +13.9% |
| Cipla Limited | ₹1.13 L Cr | ₹1,399.7 | 33.1 | 3.28 | 11.3% | 0.02 | +2.1% | -7.3% |
| Laurus Labs Limited | ₹1.09 L Cr | ₹2,007 | 100.4 | 20.52 | 16.8% | 0.48 | +22.0% | +123.9% |
| Mankind Pharma Limited | ₹1.02 L Cr | ₹2,500 | 49.0 | 6.25 | 11.7% | 0.39 | +17.0% | -1.2% |
| Max Healthcare Institute Limited | ₹1.02 L Cr | ₹1,014 | 70.0 | 9.47 | 13.4% | 0.32 | +19.0% | -10.9% |
| Dr. Reddy's Laboratories Limited | ₹99,991.95 Cr | ₹1,201 | 30.5 | 2.65 | 11.4% | 0.21 | +3.2% | -5.8% |
| SANDU PHARMACEUTICALS LTD. | ₹35.75 Cr | ₹37 | 18.8 | 0.82 | 4.0% | 0.01 | +4.1% | -22.8% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 30
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.